Survival Rate of Hepatocellular Carcinoma Patients with Varying Individual Characteristics: A Retrospective Cohort Study
Abstract
Background: There is a continuous demand for an integrated survival analysis that takes into account clinical biomarkers and socio-demographic factors in Hepatocellular carcinoma (HCC) patients from Southeast Asia. This study figured out the mortality predictors that were independent of HCC patients at a major tertiary referral center in Indonesia.
Methods: This retrospective cohort study looked into 123 HCC patients who were admitted to Dr. M. Djamil General Hospital, Padang (2018-2023). These patients were selected by simple random sampling. Survival analysis was conducted using Kaplan-Meier curves, log-rank tests, and multivariate Cox regression.
Results: Median survival was 284 days with mortality at 24.4%. Univariate analysis showed that albumin <3.5 g/dL (HR=7.67, p=0.045), AFP ≥20 ng/mL (HR=2.16, p=0.044), age ≥59 years (HR=2.38, p=0.018), and obesity (HR=3.43, p=0.013) were significantly associated factors. Multivariate Cox regression indicated that AFP level was the leading factor (adjusted HR=3.94, 95%CI: 1.67-9.33, p=0.002), followed by age ≥59 years (adjusted HR=3.52, p=0.002) and education (adjusted HR=0.36, p=0.014).
Conclusions: AFP level, old age, and education were the independent factors of HCC deaths in Central Sumatra. Besides, the conjunction of clinical and socio-demographic factors may be utilized for prognostic risk stratification to pinpoint the most at-risk groups and hence direct the targeted interventions that are most compatible with resource-limited settings predominately HBV-related HCC.Keywords
Full Text:
PDFReferences
Bachtiar, R., Parewangi, M. L., Akil, F., Daud, N. A., Kusuma, S. H., & Rifai, A. (2022). Perubahan paradigma pada strategi penanganan karsinoma hepatoseluler: Systematic review. UMI Medical Journal, 7(1), 59–71. https://doi.org/10.33096/umj.v7i1.150
Bruix, J., & Sherman, M. (2011). Management of hepatocellular carcinoma: An update. Hepatology, 53(3), 1020–1022. https://doi.org/10.1002/hep.24199
Carr, B. I., & Guerra, V. (2023). Serum inflammation parameters and survival in hepatocellular carcinoma patients: Importance of albumin and gamma-glutamyltranspeptidase. Oncology, 101(5), 313–320. https://doi.org/10.1159/000527650
Chen, F., Wu, Y., Xu, H., Song, T., & Yan, S. (2022). Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma. Scientific Reports, 12, 8573. https://doi.org/10.1038/s41598-022-14120-1
Ekinci, O., Baran, B., Ormeci, A. C., Soyer, O. M., Gokturk, S., Evirgen, S., Akyuz, F., Karaca, C., Demir, K., Besisik, F., Ozdil, S., Calıkoglu, U., Ustundag, Y., Pinarbasi, B., Oguz, D., Yilmaz, B., Yuksel, O., & Kaymakoglu, S. (2018). Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World Journal of Hepatology, 10(1), 51–61. https://doi.org/10.4254/wjh.v10.i1.51
European Association for the Study of the Liver. (2018). EASL clinical practice guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 69(1), 182–236. https://doi.org/10.1016/j.jhep.2018.03.019
European Society for Medical Oncology. (2020). Kanker hati: Panduan ESMO untuk pasien. Indonesian Society of Hematology and Medical Oncology (ISHMO).
Fadillah, M. A. M., Mashuri, M., Triawanti, T., Mulyani, N., & Rosida, A. (2022). Profil pasien karsinoma hepatoseluler yang menjalani terapi transarterial chemoembolization (TACE) di RSUD Ulin Banjarmasin periode 2016-2018. Homeostasis, 5(1), 19–28. https://doi.org/10.20527/ht.v5i1.5158
Global Cancer Observatory. (2022). Cancer today: Data visualization tools for exploring the global cancer burden in 2020. International Agency for Research on Cancer. https://gco.iarc.fr/today
Global Cancer Observatory. (2024). Cancer tomorrow: Predicted future burden to 2040. International Agency for Research on Cancer. https://gco.iarc.fr/tomorrow
Hao, X. Y., Li, A. Q., Shi, H., Guo, T. K., Shen, Y. F., Deng, Y., Cai, X. Y., Chen, Q., Luo, R. Z., & Cai, H. (2021). A novel DNA methylation-based model that effectively predicts prognosis in hepatocellular carcinoma. Bioscience Reports, 41(3), BSR20203945. https://doi.org/10.1042/BSR20203945
Huang, D. Q., Singal, A. G., Kono, Y., Tan, D. J. H., El-Serag, H. B., & Loomba, R. (2022). Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism, 34(7), 969–977. https://doi.org/10.1016/j.cmet.2022.05.003
Lee, R. M., Gamboa, A. C., Turgeon, M. K., & Yopp, A. C. (2020). Dissecting disease, race, ethnicity, and socioeconomic factors for hepatocellular carcinoma: An analysis from the United States Safety Net Collaborative. Surgical Oncology, 35, 120–125. https://doi.org/10.1016/j.suronc.2020.08.009
Liang, F., Ma, F., & Zhong, J. (2021). Prognostic factors of patients after liver cancer surgery. Medicine, 100(30), e26694. https://doi.org/10.1097/MD.0000000000026694
Liou, W. L., Tan, T. J. Y., Chen, K., Goh, G. B. B., Chang, J. P. E., & Tan, C. K. (2023). Gender survival differences in hepatocellular carcinoma: Is it all due to adherence to surveillance? A study of 1716 patients over three decades. JGH Open, 7(5), 377–386. https://doi.org/10.1002/jgh3.12910
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021). Hepatocellular carcinoma. Nature Reviews Disease Primers, 7(1), 6. https://doi.org/10.1038/s41572-020-00240-3
Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., Ferlay, J., Valery, P. C., Bray, F., & McGlynn, K. A. (2020). International trends in hepatocellular carcinoma incidence, 1978–2012. International Journal of Cancer, 147(2), 317–330. https://doi.org/10.1002/ijc.32723
Pinyopornpanish, K., Al-Yaman, W., Dasarathy, S., Romero-Marrero, C., & McCullough, A. J. (2022). Hepatocellular carcinoma in patients without cirrhosis: The fibrosis stage distribution, characteristics and survival. Digestive Diseases and Sciences, 67(6), 2677–2687. https://doi.org/10.1007/s10620-021-07048-5
Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C. J., Vignat, J., Laversanne, M., McGlynn, K. A., & Soerjomataram, I. (2022). Global burden of primary liver cancer in 2020 and predictions to 2040. Journal of Hepatology, 77(6), 1598–1606. https://doi.org/10.1016/j.jhep.2022.08.021
Sarpel, U., Heskel, M., Spivack, J. H., Feferman, Y., & Ang, C. (2018). Disparities in access to sorafenib in communities with low socioeconomic status. Journal of Health Care for the Poor and Underserved, 29(3), 1123–1134. https://doi.org/10.1353/hpu.2018.0083
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Peak, A. S., Harnois, D. M., Kamath, P. S., Tran, N. H., Gish, R. G., & Finn, R. S. (2023). AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 78(6), 1922–1965. https://doi.org/10.1097/HEP.0000000000000466
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Tim Laporan RSUP Dr. M. Djamil. (2023). Laporan tahunan Rumah Sakit Umum Pusat Dr. M. Djamil Padang tahun 2022. RSUP Dr. M. Djamil.
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology, 77(4), 1335–1347. https://doi.org/10.1097/HEP.0000000000000004
Zheng, Y., Zhang, X., Lu, J., Liu, S., & Qian, Y. (2021). Association between socioeconomic status and survival in patients with hepatocellular carcinoma. Cancer Medicine, 10(20), 7347–7359. https://doi.org/10.1002/cam4.4223
Zhou, K., Lim, T., Dodge, J. L., & Terrault, N. A. (2023). Population attributable risk of modifiable lifestyle factors to hepatocellular carcinoma: The Multiethnic Cohort. Alimentary Pharmacology & Therapeutics, 58(1), 89–98. https://doi.org/10.1111/apt.17523
DOI: http://dx.doi.org/10.33757/jik.v9i2.1408
Refbacks
- There are currently no refbacks.
Copyright (c) 2025 JIK JURNAL ILMU KESEHATAN
This work is licensed under a Creative Commons Attribution 4.0 International License.
E-ISSN : 2597-8594 (Online) P-ISSN : 2580-930X (Print)
Publish by Universitas Alifah Padang
Jl. Khatib Sulaiman No 52 B Kota Padang. Telp 0751-7059849. Fax 0751-7059849. Website: www.alifah.ac.id
Email : jik@alifah.ac.id